What is PostEra?
Founded in 2019 and headquartered in Massachusetts, PostEra is at the forefront of revolutionizing medicinal chemistry through advanced machine learning. The company offers a unique service model that leverages AI to accelerate the design and optimization of drug candidates, aiming to significantly reduce the time and cost associated with pharmaceutical research and development. This strategic application of technology positions PostEra as a key player in the biotech and pharmaceutical services sector, catering to organizations seeking to enhance their discovery pipelines with cutting-edge computational tools.
How much funding has PostEra raised?
PostEra has raised a total of $92M across 2 funding rounds:
Series A
$24M
Corporate Investment
$68M
Series A (2022): $24M with participation from Breyer Capital, I2BF Global Ventures, HOF Capital, Lifeforce Capital Gp I, The Pioneer Fund, The Clermont Group, Metaplanets, R. Martin Chavez, and ACE
Corporate Investment (2022): $68M led by National Institutes of Health
Key Investors in PostEra
Breyer Capital
Breyer Capital is a global venture capital and private equity investor founded by Jim Breyer, focusing on long-term, idea-driven investments, particularly in AI and machine learning. They have a diverse portfolio including Meta and Spotify.
I2BF Global Ventures
I2BF Global Ventures is an international technology-focused venture capital firm established in 2005, seeking innovative companies for a 'Brighter Future' and managing over $195 million across four venture capital vehicles.
HOF Capital
HOF Capital is a global technology investment firm that utilizes its extensive limited partner network to assist founders in building substantial businesses.
What's next for PostEra?
The substantial enterprise-level backing and recent strategic investment indicate PostEra is poised for significant scaling and further technological development. This capital infusion is expected to fuel the expansion of its machine learning capabilities, enhance its service offerings, and potentially broaden its market reach within the pharmaceutical and biotechnology industries. The company's focus on AI-driven drug discovery aligns with a growing trend in the sector, suggesting a strong future outlook as it continues to innovate and secure further partnerships.
See full PostEra company page
